The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

333

Participants

Timeline

Start Date

June 30, 2005

Study Completion Date

July 31, 2007

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Mitomycin C; Capecitabine; Bevacizumab

Trial Locations (36)

Unknown

Lismore Hospital, Lismore

Newcastle Mater Hospital, Newcastle

Bankstown Hospital, Sydney

Campbelltown Hospital, Sydney

Liverpool Hospital, Sydney

Nepean Hospital, Sydney

North Shore Private Hospital, Sydney

Prince of Wales Hospital, Sydney

Royal North Shore Hosp, Sydney

St George Hospital, Sydney

Sydney Cancer Centre, Concord Repat General Hospital, Sydney

Sydney Cancer Centre, Royal Prince Alfred Hospital, Sydney

Westmead Hospital, Sydney

Tamworth Base Hospital, Tamworth

Tweed Heads Hospital, Tweed Heads

Southern Medical Daycare, Wollongong

Royal Brisbane Hospital, Brisbane

Flinders Medical Centre, Adelaide

Queen Elizabeth Hospital / Lyell McEwin Centre, Adelaide

Royal Adelaide Hospital, Adelaide

Royal Hobart Hospital, Hobart

Bendigo Public Hospital, Bendigo

Geelong Hospital, Geelong

Austin Health, Melbourne

Box Hill Hospital, Melbourne

Frankston Hospital, Melbourne

Monash Medical Centre, Melbourne

Peter MacCallum Cancer Institute, Melbourne

St Vincent's Hospital, Melbourne

Border Medical Oncology, Wodonga

Fremantle Hospital, Perth

Royal Perth Hospital, Perth

Sir Charles Gairdner Hospital, Perth

St John of God Hospital, Subiaco, Perth

Christchurch Hospital, Christchurch

Palmerston North Hospital, Palmerston

All Listed Sponsors
lead

Australasian Gastro-Intestinal Trials Group

NETWORK

NCT00294359 - The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter